Pipeline

Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
Program (Cell Type) Indication CAR Target(s) Research Preclinical Phase 1 Partner
Oncology
FT576 (iNK) Multiple Myeloma BCMA

 

FT522 (iNK) B-Cell Lymphoma CD19, 41BB

 

FT819 (iT) B-Cell Malignancies CD19

 

FT825 (iT) Solid tumors HER2

 

Undisclosed Solid tumors Undisclosed

 

Ono Logo
Autoimmune Disorders
FT819 (iT) Systemic Lupus Erythmatosus CD19

 

FT522 (iNK) Undisclosed CD19, 41BB

 

Oncology

Program Indication CAR Targert(s) Phase
FT576 (iNK) Multiple Myeloma BCMA Ph 1
FT222 (iNK) B-Cell Lymphoma CD19, 41BB PreClin
FT819 (iT) B-Cell Malignancies CD19 Ph 1
FT825 (iT) Solid tumors HER2 Ph 1
Undisclosed Solid tumors Undisclosed Research

Autoimmune Disorders

Program Indication CAR Target(s) Phase
FT819 (iT) Systemic Lupus Erythmatosu CD19 Ph 1
FT222 (iNK) Undisclosed CD19, 41BB Preclin

iPSC = induced pluripotent stem cell    iNK = iPSC-derived NK Cell    iT = iPSC-derived T cell    CAR = chimeric antigen receptor